Difelikefalin: Physiology and What Research Reports
Difelikefalin is a synthetic peptide that activates kappa opioid receptors and was designed to act largely outside the central nervous system. Published trials in people receiving haemodialysis studied it for moderate-to-severe chronic kidney disease-associated itch, and reviews describe a 2021 United States approval of the intravenous form. Reported adverse events in trials and pooled analyses included diarrhoea, dizziness, nausea and vomiting. Animal work has also examined itch in atopic dermatitis models and kidney injury models.
What Difelikefalin Is
Difelikefalin is a laboratory-made peptide that acts as a selective agonist at the kappa opioid receptor. It is not a substance the human body produces; the endogenous ligands for opioid receptors are separate molecules, and difelikefalin was engineered as a synthetic analogue. A review of its development reported that difelikefalin is a peripherally restricted, selective kappa opioid receptor agonist, meaning its chemistry limits how much of it crosses into the central nervous system (PMID 34674115). That same first-approval review reported that the intravenous formulation received United States approval in 2021 for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing haemodialysis (PMID 34674115).
This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment.
Where It Acts in the Body
Kappa opioid receptors are found on sensory neurons and on immune cells as well as in the brain and spinal cord. Because difelikefalin was designed with limited central nervous system penetration, reviews of the compound have framed its intended activity as occurring on peripheral nerve endings and immune cells rather than in the brain (PMID 36102903). Reviews of chronic kidney disease-associated pruritus have discussed kappa opioid receptor agonism as a pharmacological target in that condition, where itch is often widespread, persistent and difficult to manage (PMID 33190563).
How It Is Studied and Measured
In clinical research, the outcome most often used has been a patient-reported itch intensity score. The phase 3 trial in haemodialysis patients measured change in the Worst Itching Intensity Numerical Rating Scale and reported the proportion of participants achieving at least a 3-point decrease from baseline, alongside itch-related quality-of-life instruments (PMID 31702883). In preclinical research, scratching behaviour is counted directly: a murine study of atopic dermatitis reported that difelikefalin suppressed itch and reduced scratching independent of inflammation (PMID 37453613).
What the Clinical Literature Reports
The pivotal randomised trial enrolled patients undergoing haemodialysis with moderate-to-severe pruritus and, as the study described, administered intravenous difelikefalin at 0.5 µg per kilogram three times weekly for 12 weeks compared with placebo, with researchers reporting a greater proportion of patients reaching at least a 3-point improvement in the itch intensity score in the difelikefalin group (PMID 31702883).
Subsequent syntheses have pooled the randomised evidence. A systematic review and meta-analysis in haemodialysis patients with pruritus reported improvement in itch scores with difelikefalin relative to placebo (PMID 39712488), and a separate meta-analysis and systematic review examined both efficacy and safety in the same population (PMID 38294219). An earlier systematic review of difelikefalin in chronic kidney disease-associated pruritus summarised the trial programme and reported consistent direction of effect on itch outcomes (PMID 36015082). Narrative reviews have covered the pharmacology and clinical positioning of the intravenous formulation in haemodialysis pruritus (PMID 37847514) and its pharmacokinetics and clinical use in moderate-to-severe chronic kidney disease-associated pruritus (PMID 37010031). A pharmacotherapy review characterised difelikefalin as a new kappa opioid receptor agonist for haemodialysis-dependent chronic kidney disease-associated pruritus (PMID 35942600).
| Source type | Population or model | What researchers reported |
|---|---|---|
| Phase 3 randomised trial | Haemodialysis patients with moderate-to-severe pruritus | Intravenous difelikefalin 0.5 µg/kg three times weekly for 12 weeks improved itch intensity scores versus placebo (PMID 31702883) |
| Meta-analysis | Haemodialysis patients with pruritus | Pooled data reported improvement in itch outcomes with difelikefalin (PMID 39712488) |
| Animal study | Murine atopic dermatitis model | Difelikefalin suppressed itch and reduced scratching independent of inflammation (PMID 37453613) |
| Animal study | Rat renal ischaemia-reperfusion acute kidney injury | Researchers reported anti-inflammatory and renoprotective effects of the kappa opioid receptor agonist (PMID 40596915) |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freePreclinical Research Beyond Itch
Two lines of animal work extend the picture of what kappa opioid receptor agonism can do. In a murine atopic dermatitis model, the study reported that difelikefalin suppressed itch and reduced scratching without depending on a reduction in skin inflammation, which researchers interpreted as a neuronal rather than purely immunological mechanism (PMID 37453613). In a rat model of renal ischaemia-reperfusion-induced acute kidney injury, researchers reported anti-inflammatory and renoprotective effects of difelikefalin (PMID 40596915). Findings in rodents do not establish the same outcomes in humans, and neither study was a clinical trial.
Adverse Events: What Studies Report
The phase 3 trial reported that diarrhoea, dizziness and vomiting occurred more frequently among participants who received difelikefalin than among those who received placebo over the 12-week treatment period (PMID 31702883). A meta-analysis and systematic review that assessed both efficacy and safety in haemodialysis patients with pruritus examined the pooled rates of adverse events across randomised trials (PMID 38294219), and a second pooled analysis also reported on tolerability alongside itch outcomes (PMID 39712488). Reviews of the compound have discussed the rationale for peripheral restriction in relation to the sedation and dysphoria historically associated with centrally acting kappa opioid receptor agonists (PMID 34674115), and a systematic review summarised the safety data available across the difelikefalin trial programme (PMID 36015082).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appWhy the Term Matters to Readers
Difelikefalin is one of the clearest examples of a synthetic peptide moving from receptor pharmacology to an approved medicine, which is why it appears frequently in peptide reading lists. It illustrates three ideas at once: that a peptide can be engineered to stay out of the brain, that a receptor family long associated with central effects can be targeted peripherally, and that regulatory approval rests on a defined population, route and endpoint rather than general claims. The approved product described in the literature was an intravenous formulation for a specific haemodialysis population (PMID 34674115), not a general-purpose agent.
Limits of the Evidence
The clinical evidence base centres on adults with chronic kidney disease-associated pruritus who are receiving haemodialysis, and reviews have noted that this is the population in which difelikefalin has been studied most (PMID 37010031). Trial durations in the randomised evidence have been measured in weeks rather than years (PMID 31702883), and other itch conditions remain areas of investigation rather than settled evidence. Readers who encounter the name in supplier listings or forums should note that research-use-only material is not the same as an approved, quality-controlled medicine.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- Difelikefalin: First Approval (Drugs, 2021)
- A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus (The New England Journal of Medicine, 2020)
- Intravenous difelikefalin for the treatment of hemodialysis pruritus (Expert Review of Clinical Immunology, 2024)
- Difelikefalin for pruritus associated with renal disease (Drugs of Today, 2022)
- Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis (The Journal of Allergy and Clinical Immunology, 2023)
- Anti-inflammatory and renoprotective effects of difelikefalin, a kappa opioid receptor agonist, in a rat model of renal ischemia-reperfusion-induced acute kidney injury (BMC Nephrology, 2025)
- An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease (Expert Opinion on Pharmacotherapy, 2021)
- Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis (Expert Review of Clinical Pharmacology, 2023)
- Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis (Frontiers in Pharmacology, 2024)
- Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus (The Annals of Pharmacotherapy, 2023)
- Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review (Pharmaceuticals, 2022)
- Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review (Clinical Nephrology, 2024)
Frequently asked questions
What is difelikefalin?▾
Difelikefalin is a synthetic peptide that acts as a selective kappa opioid receptor agonist. A first-approval review described it as peripherally restricted, meaning it was designed with limited entry into the central nervous system, and reported United States approval of the intravenous form in 2021 for moderate-to-severe pruritus associated with chronic kidney disease in adults on haemodialysis (PMID 34674115).
What adverse events did trials report?▾
The phase 3 haemodialysis trial reported diarrhoea, dizziness and vomiting more often in the difelikefalin group than the placebo group during the 12-week treatment period (PMID 31702883). Pooled analyses of randomised trials also assessed safety and tolerability alongside itch outcomes in this population (PMID 38294219; PMID 39712488). Safety findings apply to the studied population only.
What did the phase 3 trial measure?▾
The study enrolled haemodialysis patients with moderate-to-severe pruritus and, as researchers reported, used intravenous difelikefalin at 0.5 µg per kilogram three times weekly for 12 weeks versus placebo, with the main outcome being the proportion achieving at least a 3-point improvement on the Worst Itching Intensity Numerical Rating Scale (PMID 31702883).
Has difelikefalin been studied outside kidney disease?▾
Yes, in animals. A murine atopic dermatitis study reported that difelikefalin suppressed itch and reduced scratching independent of inflammation (PMID 37453613), and a rat model of renal ischaemia-reperfusion acute kidney injury reported anti-inflammatory and renoprotective effects (PMID 40596915). Rodent findings do not establish equivalent outcomes in humans and are not clinical evidence.
Why was difelikefalin designed to stay outside the brain?▾
Reviews of its development explained that peripheral restriction was intended to engage kappa opioid receptors on sensory neurons and immune cells while limiting central effects historically associated with centrally acting kappa agonists (PMID 34674115). Narrative reviews of chronic kidney disease-associated pruritus have discussed this receptor as a pharmacological target for itch (PMID 36102903; PMID 33190563).
What do meta-analyses conclude?▾
A systematic review and meta-analysis in haemodialysis patients with pruritus reported improvement in itch scores with difelikefalin compared with placebo (PMID 39712488). A separate meta-analysis and systematic review evaluated efficacy and safety together (PMID 38294219), and an earlier systematic review summarised the trial programme in chronic kidney disease-associated pruritus (PMID 36015082).
What are the limits of the current evidence?▾
Published clinical research centres on adults with chronic kidney disease-associated pruritus receiving haemodialysis, as reviews of its clinical pharmacology describe (PMID 37010031; PMID 35942600), and randomised treatment periods were measured in weeks rather than years (PMID 31702883). This page is educational only and is not medical advice; consult a licensed physician.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.